AI Offers New Pathways to Strengthen Site Leadership in Underserved Regions
Artificial intelligence can help identify key opinion leaders in emerging markets, improving site influence, patient engagement, and trial success.
Gen Li, PhD, MBA, president of Phesi, discussed the company's analysis on global inequity in breast cancer development in a recent video interview with Applied Clinical Trials.
Operational barriers in lower-income countries are attributed to traditional business models, with opportunities to implement a more patient-centric approach by leveraging artificial intelligence (AI) and machine learning.
Li emphasized the importance of identifying local leaders and redistributing trial workloads to improve recruitment using AI.
- Geographic concentration of breast cancer trial leaders in the US and China
- Opportunities for global diversity and patient-centric approaches
- Need to identify and activate new sites using AI
Author's summary: AI helps identify key opinion leaders in emerging markets.
More News
- Benz Hui Dies At 76 from Cancer-Related Organ Failure
- "No" to the Mandate for Purchasing Zero-Emission Trucks. IRU Appeals to Brussels for Reason
- Huawei showcases grid-forming BESS at 2nd Philippines Future Energy and Grid Summit
- Major Candy Company Files Chapter 11 Bankruptcy Amid Halloween Week Shock - CCE l ONLINE NEWS
- US Weekly Headlines: Policy change for Pentagon officials, government shutdown continues
- Australia’s clean energy pipeline grows 24% to 56.6 GW
- Antifa Terrorism Charges: A Victory for Law Enforcement
- Saudi Arabia's BRKZ lands $30 million debt from Stride Ventures